Agios Pharmaceuticals, Inc.
AGIO
$29.45
$0.190.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 291.35% | 407.03% | -73.74% | -61.72% | -51.89% |
| Total Depreciation and Amortization | -14.65% | -19.12% | -19.28% | -21.52% | -22.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,632.94% | -1,531.80% | 183.81% | 185.93% | 198.07% |
| Change in Net Operating Assets | -3.73% | 340.60% | -4.68% | -25.98% | -15.97% |
| Cash from Operations | -31.68% | -13.61% | -2.39% | 2.01% | 4.34% |
| Capital Expenditure | -68.67% | -8.43% | -64.90% | 70.07% | 79.53% |
| Sale of Property, Plant, and Equipment | -96.98% | -98.25% | 9.07% | 9.07% | 37.45% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -31.00% | 36.98% | 1.78% | -6.91% | -3.21% |
| Cash from Investing | 51.70% | 123.83% | 1.69% | -6.38% | -1.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 165.82% | 122.70% | 137.55% | 128.82% | 102.65% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 165.82% | 126.71% | 147.69% | 144.67% | 131.19% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.58% | 425.89% | 93.80% | -39.35% | 20.06% |